BA2101 / Luye Group, Joincare, Shandong Boan Biotechnology - LARVOL DELTA

Boan Biotech (06955) and Joincare signed an exclusive licensing cooperation agreement for BA2101 injection [Google translation] (Investing.com) - "Boan Biotech...announced that the company has signed an agreement with Joincare Pharmaceutical Group Co., Ltd. (Jointcare). The agreement involves the exclusive licensing, development and commercialization of the company’s product under development, BA2101 injection, for indications in the treatment of asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. According to the agreement, the company will grant Joincare the exclusive rights to develop, register, produce and commercialize the product for indications in this field in mainland China. The company continues to hold the relevant rights of the product for all other indications outside the agreement area, as well as all rights for the product for all indications outside the agreement area."

Licensing / partnership • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Anxin International: The performance of Boan Biological (06955) is expected to be greatly improved due to the heavy volume of various products and the imminent listing [Google translation] (Investing.com) - "BA2101 (long-acting IL4R monoclonal antibody) has entered Phase 1 clinical trials in China and is expected to complete Phase 1 clinical trials for SAD by the end of 2023; BA1106 (non-IL-2 blocking anti-CD25 monoclonal antibody) has entered Phase 1 clinical trials in China. It is expected to complete the Phase 1 SAD clinical trial in 2024; BA1105 (ADCC enhanced Claudin 18.2 monoclonal antibody) has entered the Phase 1 clinical trial in China, and is expected to complete the Phase 1 SAD clinical trial by the end of 2023; BA1301 (Claudin 18.2 ADC) has obtained IND approval is expected to start phase 1 clinical trial in the second quarter of 2023; BA1202 (CEA/CD3 double antibody) is expected to receive IND approval in the first half of 2023."

IND • New P1 trial • Gastrointestinal Cancer • Immunology • Oncology • Solid Tumor